Progress in pathogenesis and therapy of Rasmussen's encephalitis

Area of Science:

• Neurology
• Immunology
• Genetics

Background:

• Rasmussen's encephalitis (RE) is a rare, severe neurological disorder primarily affecting children.
• Characterized by drug-resistant seizures, unilateral hemispheric atrophy, and progressive neurological deficits.
• Etiology remains largely unknown, complicating treatment strategies.

Purpose of the Study:

• To review current research on the pathogenesis of Rasmussen's encephalitis.
• To explore potential therapeutic targets based on emerging understanding of RE mechanisms.
• To discuss the challenges and advancements in managing RE.

Main Methods:

• Literature review of studies on RE pathogenesis.
• Analysis of research on viral, autoimmune, immune-mediated, and genetic factors.
• Evaluation of current and potential treatment strategies, including immunotherapy and surgery.

Main Results:

• Five proposed pathogenetic mechanisms include viral infection, antibody-mediated degeneration, cell-mediated immunity, microglia-induced degeneration, and genetic mutations.
• No definitive virus or antigen identified; however, cytotoxic CD8+ T lymphocytes and activated microglia play significant roles.
• Genetic research points to single nucleotide polymorphisms in immune-related genes affecting innate immunity.
• Immunotherapy shows potential in slowing RE progression by targeting early immune damage.
• Cerebral hemispherectomy effectively controls seizures but has inevitable complications.

Conclusions:

• The pathogenesis of RE is complex, involving intricate immune responses and genetic predispositions.
• Targeting T cells and microglia early in the disease course may offer therapeutic benefits.
• Optimizing surgical intervention timing remains a clinical challenge.
• Further research into factors like adenosine system dysfunction may reveal novel treatment avenues.